USE OF THE BASIC FORM OF RECOMBINANT HUMAN ERYTHROPOIETIN IN THE TREATMENT OF PATIENTS WITH SPINOCEREBELLAR ATAXIA WITH CAG REPEAT MUTATIONS

The present invention relates to use of pharmaceutical compositions that have as active ingredient the basic form of recombinant human erythropoietin (rhEPO) and that are administered nasally for the treatment of spinocerebellar ataxia (SCA) with mutations of CAG repeats type, particularly of SCA ty...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	JIMÉNEZ RODRÍGUEZ, Daise, AMARO GONZÁLEZ, Daniel Enrique, JAY PÉREZ, Daniel, GONZÁLEZ TRIANA, Consuelo, RODRÍGUEZ LABRADA, Roberto, ORTEGA SÁNCHEZ, Ricardo, SOSA TESTÉ, Iliana María, GARCÍA RODRÍGUEZ, Julio César, HERNÁNDEZ CASAÑA, Patricia, VELÁZQUEZ PÉREZ, Luis Clodoaldo, LÓPEZ MATILLA, Lien
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to use of pharmaceutical compositions that have as active ingredient the basic form of recombinant human erythropoietin (rhEPO) and that are administered nasally for the treatment of spinocerebellar ataxia (SCA) with mutations of CAG repeats type, particularly of SCA type 2. Another object of the present invention is a method for stratifying patients into responders and non-responders to treatment with the basic form of rhEPO.